Want to see HK:6667 full AI Analyst Report?
Mega Genomics Limited (6667) AI Stock Analysis
Mega Genomics Limited
(HKEX:6667)
The score is primarily supported by a strong, low-leverage balance sheet, but is held back by weak latest-year cash flow (negative operating and free cash flow) and reduced profitability versus earlier peak years. Technicals are mildly weak with negative MACD and price slightly below major moving averages, while valuation is a further headwind due to a high P/E despite a moderate dividend yield.
Mega Genomics Limited (6667) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.59B
- Dividend Yield
- 2.40%
- Average Volume (3M)
- 65.42K
- Price to Earnings (P/E)
- 50.5
- Beta (1Y)
- -0.17
- Revenue Growth
- 169.02%
- EPS Growth
- -24.61%
- Country
- Hong Kong
- Employees
- 196
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Mega Genomics Limited Business Overview & Revenue Model
Company Description
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzh...
Mega Genomics Limited Financial Statement Overview
Summary
Balance sheet strength is a key positive (very low leverage and substantial equity), but operating quality is mixed: profitability remains positive with strong recent revenue growth, yet margins have compressed materially and net income fell despite higher sales. The largest drag is cash flow, with both operating cash flow and free cash flow turning negative in the latest year, raising concerns about cash conversion consistency.
Income Statement
66PositiveBalance Sheet
84Very PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 355.81M | 164.23M | 247.15M | 151.30M | 145.73M | 237.19M |
| Gross Profit | 120.01M | 119.35M | 117.36M | 88.30M | 81.72M | 166.68M |
| EBITDA | 43.31M | 70.03M | 49.68M | 52.42M | -5.42M | 116.67M |
| Net Income | 24.54M | 45.05M | 27.02M | 30.04M | -17.62M | 79.02M |
Balance Sheet | ||||||
| Total Assets | 829.81M | 738.48M | 832.40M | 796.54M | 705.70M | 772.18M |
| Cash, Cash Equivalents and Short-Term Investments | 424.49M | 490.26M | 435.70M | 518.29M | 399.83M | 239.10M |
| Total Debt | 28.52M | 34.40M | 29.37M | 48.56M | 10.99M | 11.57M |
| Total Liabilities | 224.37M | 123.80M | 221.46M | 151.72M | 87.70M | 77.69M |
| Stockholders Equity | 605.44M | 614.68M | 610.94M | 644.83M | 618.00M | 694.50M |
Cash Flow | ||||||
| Free Cash Flow | 857.74K | 56.38M | -16.68M | 127.59M | -12.10M | 26.21M |
| Operating Cash Flow | 950.88K | 57.15M | -16.52M | 163.68M | -6.91M | 30.63M |
| Investing Cash Flow | 166.68K | 6.63M | -16.88M | -33.75M | -2.56M | -1.71M |
| Financing Cash Flow | -35.93M | -91.85M | -41.27M | -12.91M | 158.46M | 2.62M |
Mega Genomics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6667, the sentiment is Positive. The current price of 7.08 is below the 20-day moving average (MA) of 7.12, below the 50-day MA of 7.08, and above the 200-day MA of 7.02, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 49.36 is Neutral, neither overbought nor oversold. The STOCH value of 48.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6667.
Mega Genomics Limited Peers Comparison
Overall Rating
HK:235975Outperform
HK:666961.6Neutral- HK:666754Neutral
HK:996051Neutral
HK:193126Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2359 | 75Outperform | HKD 506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% |
| HK:6669 | 62Neutral | HKD 1.64B | -27.72 | -3.50% | ― | 9.36% | -153.54% |
| HK:6667 | 54Neutral | HKD 1.59B | 50.49 | 4.04% | 2.40% | 169.02% | -24.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9960 | 51Neutral | HKD 931.99M | -18.57 | -1.56% | 10.61% | 7.95% | 60.86% |
| HK:1931 | 26Underperform | HKD 575.63M | -6.46 | -2.60% | ― | -2.55% | -145.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6667 | Mega Genomics Limited | 7.08 | 0.05 | 0.68% | |
| HK:6669 | Acotec Scientific Holdings Limited | 5.22 | -6.87 | -56.82% | |
| HK:9960 | Kindstar Globalgene Technology, Inc. | 0.90 | -0.30 | -25.42% | |
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.93 | -94.35% | |
| HK:2359 | WuXi AppTec Co., Ltd. Class H | 185.40 | 83.35 | 81.67% | |
| HK:2566 | Hangzhou Jiuyuan Gene Engineering Co Ltd Class H | 4.98 | -3.17 | -38.87% |
Mega Genomics Limited Corporate Events
Mega Genomics Accelerates Revenue Growth as Product Mix Shift Pressures Profit
Mega Genomics reported strong top-line momentum for the six months ended 30 June 2026, with operating revenue rising 136.8% year-on-year to RMB192.5 million on the back of expanded product categories and an optimized product structure. The interim fi...
Mega Genomics Sets Board Meeting to Approve Interim Results and Consider Dividend
Mega Genomics Limited has scheduled a board meeting for 31 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend and address any...
Mega Genomics Revamps Hong Kong Governance Roles and Relocates Principal Office
Mega Genomics Limited has announced changes to its key corporate governance roles in Hong Kong, including the appointment of a new company secretary, authorised representative and process agent. These positions are central to the company’s comp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 22, 2026